Studies have found patients with HeFH to have a higher risk of ASCVD, and that lowering Lp(a) level by 50 mg/dL (125 nmol/L) for a short period (i.e., five years) reduces ASCVD by 20% in a secondary prevention setting in the general population; hence, there is a need for studies aimed at determining the safe level of Lp(a) for patients with HeFH. Here, LPA is linked to atherosclerosis.